AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
India
· Delayed Price · Currency is INR 8,314.50
-102.00 (-1.21%)
Aug 14, 2025, 3:30 PM IST
AstraZeneca Pharma India Revenue
In the fiscal year ending March 31, 2025, AstraZeneca Pharma India had annual revenue of 17.16B INR with 32.48% growth. AstraZeneca Pharma India had revenue of 4.80B in the quarter ending March 31, 2025, with 25.39% growth.
Revenue
17.16B
Revenue Growth
+32.48%
P/S Ratio
12.26
Revenue / Employee
21.40M
Employees
802
Market Cap
210.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | 8.14B | -182.50M | -2.19% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 80.94B |
| Aurobindo Pharma | 320.25B |
AstraZeneca Pharma India News
- 6 hours ago - AstraZeneca Pharma shares rise over 2% after company swings back to profit in Q1 - Business Upturn
- 6 hours ago - AstraZeneca Pharma Q1 Results: Revenue up 36% YoY to Rs 526 crore, Net Profit at Rs 55 crore - Business Upturn
- 4 weeks ago - AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication - Business Upturn
- 2 months ago - AstraZeneca Pharma India shares rally over 7% after strong Q4 results - Business Upturn
- 2 months ago - AstraZeneca Pharma receives CDSCO nod for expanded use of Fasenra in India - Business Upturn
- 5 months ago - AstraZeneca Pharma gets approval for additional indication of Durvalumab (Imfinzi) in India - Business Upturn
- 5 months ago - AstraZeneca receives approval to import Lokelma for hyperkalaemia treatment in India - Business Upturn
- 7 months ago - AstraZeneca receives approval to import and distribute Eculizumab - Business Upturn